Search Page

1

Cite

Share

The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance.

Peyrani P, Mandell L, Torres A, Tillotson GS. Peyrani P, et al. Among authors: tillotson gs. Expert Rev Respir Med. 2019 Feb;13(2):139-152. doi: 10.1080/17476348.2019.1562339. Epub 2018 Dec 30. Expert Rev Respir Med. 2019. PMID: 30596308 Review.

Cite

Share

2

Cite

Share

Antibiotic resistance: the challenge from an industry perspective.

Tillotson GS. Tillotson GS. Expert Rev Clin Pharmacol. 2009 Mar;2(2):119-23. doi: 10.1586/17512433.2.2.119. Expert Rev Clin Pharmacol. 2009. PMID: 24410641

Cite

Share

3

Cite

Share

Rebuttal From Dr Tillotson.

Tillotson GS. Tillotson GS. Chest. 2016 May;149(5):1133-5. doi: 10.1016/j.chest.2016.01.027. Chest. 2016. PMID: 27157215 No abstract available.

Cite

Share

4

Cite

Share

A new dawn for the management of influenza?

Tillotson GS. Tillotson GS. Lancet Infect Dis. 2020 Oct;20(10):1112-1114. doi: 10.1016/S1473-3099(20)30459-X. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526194 Free PMC article. No abstract available.

Cite

Share

5

Cite

Share

Clostridioides difficile Infection: The Challenge, Tests, and Guidelines.

Lyerly DM, Boone JH, Carman RJ, Tillotson GS. Lyerly DM, et al. Among authors: tillotson gs. ACS Infect Dis. 2020 Nov 13;6(11):2818-2829. doi: 10.1021/acsinfecdis.0c00290. Epub 2020 Oct 2. ACS Infect Dis. 2020. PMID: 32960044

Cite

Share

6

Cite

Share

Real-World Use of Oritavancin for the Treatment of Osteomyelitis.

Scoble PJ, Reilly J, Tillotson GS. Scoble PJ, et al. Among authors: tillotson gs. Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):46-54. doi: 10.1007/s40801-020-00194-8. Drugs Real World Outcomes. 2020. PMID: 32588387 Free PMC article. Review.

Cite

Share

7

Cite

Share

Screening for Methicillin resistant Staphylococcus aureus (MRSA) - a valuable antimicrobial stewardship tool?

Tillotson GS, van Hise N. Tillotson GS, et al. Expert Rev Anti Infect Ther. 2021 Aug;19(8):957-959. doi: 10.1080/14787210.2021.1865800. Epub 2020 Dec 24. Expert Rev Anti Infect Ther. 2021. PMID: 33331192 No abstract available.

Cite

Share

8

Cite

Share

Difficult to Treat: Do We Need a New Definition?

Echols RM, Tillotson GS. Echols RM, et al. Among authors: tillotson gs. Clin Infect Dis. 2019 Oct 15;69(9):1641-1642. doi: 10.1093/cid/ciz184. Clin Infect Dis. 2019. PMID: 30838418 No abstract available.

Cite

Share

9

Cite

Share

Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance?

Tillotson GS. Tillotson GS. Infect Dis (Auckl). 2016 Oct 11;9:45-52. doi: 10.4137/IDRT.S31567. eCollection 2016. Infect Dis (Auckl). 2016. PMID: 27773991 Free PMC article. Review.

Cite

Share

10

Cite

Share

New and alternative approaches to tackling antibiotic resistance.

Tillotson GS, Theriault N. Tillotson GS, et al. F1000Prime Rep. 2013 Dec 3;5:51. doi: 10.12703/P5-51. F1000Prime Rep. 2013. PMID: 24381727 Free PMC article. Review.

Cite

Share